SNW2 Stock Overview
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Sanofi Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €46.00 |
| 52 Week High | €52.50 |
| 52 Week Low | €42.20 |
| Beta | 0.45 |
| 11 Month Change | -7.63% |
| 3 Month Change | -8.00% |
| 1 Year Change | 5.99% |
| 33 Year Change | 10.58% |
| 5 Year Change | 9.00% |
| Change since IPO | 57.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| SNW2 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.7% | -1.0% | 0.2% |
| 1Y | 6.0% | -19.3% | 8.5% |
Return vs Industry: SNW2 exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: SNW2 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| SNW2 volatility | |
|---|---|
| SNW2 Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: SNW2 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SNW2's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 86,088 | Paul Hudson | www.sanofi.com |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Sanofi Fundamentals Summary
| SNW2 fundamental statistics | |
|---|---|
| Market cap | €116.80b |
| Earnings (TTM) | €4.51b |
| Revenue (TTM) | €48.45b |
25.9x
P/E Ratio2.4x
P/S RatioIs SNW2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNW2 income statement (TTM) | |
|---|---|
| Revenue | €48.45b |
| Cost of Revenue | €14.96b |
| Gross Profit | €33.48b |
| Other Expenses | €28.98b |
| Earnings | €4.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | 3.59 |
| Gross Margin | 69.12% |
| Net Profit Margin | 9.30% |
| Debt/Equity Ratio | 32.5% |
How did SNW2 perform over the long term?
See historical performance and comparison